NEXGEL, Inc. (NXGL) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

NEXGEL, Inc.

NXGL

NASDAQ

Unprofitable

Unprofitable

23M

Medical - Instruments & Supplies

Next Earning date - 11 Nov 2024

23M

Medical - Instruments & Supplies

Next Earning date - 11 Nov 2024

2.48USD

0.07 ( 2.90%)

Relative Strenght

23

Volume Buzz

-84%

Earning Acce

No

Dist 52w H.

23%

Quote Panel

Updated October 4, 2024

1W -3.49 % 1M -12.32 % 3M 12.67 % 1Y 26.40 %

Key Metrics

Market Cap
23.20M
Shares Outstanding
9.35M
Share in Float
7.11M
Dividende
0

Earning Date
11 Nov 2024
Price Target
2.48
Average Volume
52917
Beta
0.754

Range
1.46-3.24
Industry
Medical - Instruments & Supplies
Website
https://nexgel.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

4.50x

P/S Ratio

3.62x

P/B Ratio

0.2

Debt/Equity

-67.6%

Net Margin

$-0.6

EPS

How NXGL compares to sector?

P/E Ratio

Relative Strength

NXGL

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$11M

686%

2025-Revenue

$0.01

93%

2025-EPS

$11M

-1009%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Maxim Group

initialise

Previous: Not converted

2022-02-25

Now: Buy

Earnings Growth

YoY

Current

Estimates

Q3.22

N/A

-0.22
vs -0.23

Q4.22

N/A

-0.11
vs -0.29

Q1.23

N/A

-0.15
vs -0.33

Q2.23

N/A

-0.12
vs -0.19

Q3.23

N/A

-0.10
vs -0.22

Q4.23

N/A

-0.19
vs -0.11

Q1.24

N/A

-0.14
vs -0.15

Q2.24

N/A

-0.14
vs -0.12

Q3.24

N/A

-0.12
vs -0.10

Q4.24

N/A

-0.11
vs -0.19

Sales Growth

YoY

Current

Estimates

Q3.22

+70%

568K vs 335K

Q4.22

-2%

524K vs 533K

Q1.23

+57%

620K vs 396K

Q2.23

+108%

1.2M vs 561K

Q3.23

+115%

1.2M vs 568K

Q4.23

+106%

1.1M vs 524K

Q1.24

+104%

1.3M vs 620K

Q2.24

+23%

1.4M vs 1.2M

Q3.24

+71%

2.1M vs 1.2M

Q4.24

+128%

2.5M vs 1.1M

Return on Equity

QoQ

Q3.22

-17%

-0.17
vs -0.14

Q4.22

-7%

-0.07
vs -0.17

Q1.23

-12%

-0.12
vs -0.07

Q2.23

-11%

-0.11
vs -0.12

Q3.23

-10%

-0.10
vs -0.11

Q4.23

-23%

-0.23
vs -0.10

Q1.24

-18%

-0.18
vs -0.23

Q2.24

-21%

-0.21
vs -0.18

Institutionnal Ownership

QoQ

Q3.22

7

7
vs 7

NA

Q4.22

8

8
vs 7

14%

Q1.23

8

8
vs 8

NA

Q2.23

11

11
vs 8

38%

Q3.23

9

9
vs 11

-18%

Q4.23

9

9
vs 9

NA

Q1.24

12

12
vs 9

33%

Q2.24

11

11
vs 12

-8%

Earnings Growth

Latest News

NXGL

globenewswire.com

8 hours ago

NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America

NXGL

globenewswire.com

9 hours ago

NEXGEL to Report Second Quarter 2024 Financial Results on August 14th

NXGL

globenewswire.com

9 hours ago

NEXGEL and Innovative Optics US Initiate Institutional Review Board (IRB) Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal

NXGL

globenewswire.com

16 hours ago

NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million

NXGL

globenewswire.com

16 hours ago

NEXGEL Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of 2024 of $2.2 Million and $2.6 Million, Respectively

NXGL

seekingalpha.com

21 hours ago

NEXGEL, Inc. (NXGL) Q2 2024 Earnings Call Transcript

New Feature Coming Soon, Stay Tuned!

Shape

Shape